Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Summary Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to
improved outcomes at all stages of liver disease. However, available data suggest that the …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver
Cancer (BCLC)-B/C hepatocellular carcinoma (HCC) is understudied. HCC patients have …

The transition from compensated to decompensated cirrhosis results from a complex
interplay of predisposing and precipitating factors and represents an inflection point in the …

Patients with decompensated cirrhosis are currently managed through targeted strategies
aimed at preventing or treating specific complications. In contrast, a disease-modifying agent …

Background & Aims Recognition of non-characterized liver nodules (NCLN) prior to direct-
acting antivirals (DAAs) is associated with increased hepatocellular carcinoma (HCC) risk in …

Background It is unclear whether the fibrosis 4 index (FIB-4), a marker of liver fibrosis, at
baseline and change in FIB-4 after sustained virological response (SVR) is associated with …

Summary Background The World Health Organization (WHO) set a goal to eliminate
hepatitis C (HCV) infection globally by 2030, with specific targets to reduce new viral …

Treatment of hepatitis C (HCV) has been revolutionized with the introduction of direct-acting
antivirals (DAAs). Patients can be treated at more advanced stages of liver disease, with a …